News

Alkermes plc's Strong Financial Growth in Q3 2024

Alkermes plc's Strong Financial Growth in Q3 2024

Alkermes Reports Third Quarter Financial Results

Alkermes plc announced robust financial outcomes for its third quarter, achieving revenues of $378.1 million. This impressive figure marks a nearly 18% increase in net sales of proprietary products year-over-year. The Company’s solid performance stems from its diverse product portfolio and strong market demand.

Key Financial Highlights

During the third quarter, Alkermes achieved a GAAP net income of $92.8 million, which translates to diluted earnings per share of $0.56. These results indicate a continued commitment to delivering value to shareholders through profitable operations.

Driving Factors of Growth

Richard Pops, Chief Executive Officer, stated, "Our third-quarter financial results reflect strong year-over-year growth in our proprietary commercial products. We are well-positioned to enhance our strategic goals while advancing our innovative pipeline, particularly with ALKS 2680, our novel investigational orexin 2 receptor agonist. This is expected to drive significant shareholder value. The upcoming year holds potential for transformative advancements for Alkermes as we complete ongoing studies in narcolepsy types 1 and 2, preparing for possible registrational studies. Orexin 2 receptor agonists present a thrilling opportunity across various symptomatic domains of treatment, which we believe will benefit our shareholders profoundly."

Revenue Distribution

Among the proprietary products, VIVITROL generated revenues of $113.7 million, marking a 14% increment compared to the same quarter last year. ALKS’s LYBALVI also saw remarkable growth, documenting revenues of $74.7 million—a significant 47% rise in prescriptions. Furthermore, ARISTADA achieved revenues of $84.7 million during the quarter, affirming the strong presence of Alkermes in the market.

Strategic Financial Operations

Continuing its focus on building shareholder equity, Alkermes reiterated its financial expectations for 2024, displaying confidence in its strategic initiatives aimed at scaling operations effectively. Its balance sheet reflects continued strength, with cash and equivalents totaling approximately $927.8 million by the end of September.

Investments in Future Potential

Alkermes is actively managing resource allocation to foster growth in its proprietary product lines while investing in the development of novel therapies. This commitment not only seeks to drive future revenues but also to enhance the company's overall risk profile through innovative product pipelines.

Share Repurchase Initiatives

In alignment with its financial strategies, Alkermes repurchased approximately 4.4 million ordinary shares during the quarter under its existing buyback program, involving total expenditures of $115.6 million. This maneuver reinforces the company’s dedication to returning value to shareholders while maintaining a healthy financial standing.

Frequently Asked Questions

What were Alkermes plc's total revenues for the third quarter of 2024?

Alkermes plc reported total revenues of $378.1 million for the third quarter of 2024.

How has ALKS 2680's development progressed?

ALKS 2680 is undergoing ongoing phase 2 studies, with potential plans for registrational studies in the near future.

What key products contributed to Alkermes' revenue growth?

The primary drivers of revenue included VIVITROL, LYBALVI, and ARISTADA, which collectively bolstered the company’s earnings.

What is Alkermes' approach to managing its capital structure?

Alkermes focuses on leveraging its cash position to fund strategic initiatives and return capital to shareholders through share repurchase programs.

What are the future financial expectations for Alkermes?

The company has reaffirmed its financial expectations for 2024, indicating confidence in its operational strategies and product pipeline.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 319

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 224

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 181

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 98

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 158

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Crest Auto Group Teams Up with Football Star Kevin Jennings

Updated Category News Views 228

Crest Auto Group Partners with Rising Star Kevin Jennings Crest Auto Group, a renowned automotive dealership with a strong legacy in the industry, is taking a giant leap forward by announcing its inaugural collegiate Name, Image, and Likeness (NIL) partnership with the exceptional Kevin Jennings. As a team captain and quarterback, Jennings hails from a community that...

Continue Reading
Carolwood Estates Celebrates a Stellar 2024 Year of Growth

Updated Category News Views 390

Carolwood Estates Unveils Its 2024 Annual Report In a remarkable demonstration of resilience and success, Carolwood Estates has released its 2024 Annual Report, shining a spotlight on a fabulous year filled with record-breaking accomplishments. Under the leadership of CEO Drew Fenton, the brokerage has made notable strides within the competitive landscape of luxury real...

Continue Reading
Savage Appoints Josh Anders as Strategic Chief Financial Officer

Updated Category News Views 896

Welcoming Josh Anders to Savage Leadership Savage is thrilled to announce the appointment of Josh Anders as the new Chief Financial Officer (CFO) of the company. With a strong background in finance and a wealth of experience in various financial leadership roles, Anders is set to join the ranks of Savage’s effective global supply chain team. Experience and Leadership...

Continue Reading
John Hardin Enhances UBS Private Wealth Management Team in Miami

Updated Category News Views 91

UBS Welcomes New Financial Advisor in Miami UBS Private Wealth Management is making significant strides in enhancing its service offerings in South Florida with the inclusion of John Hardin as a Financial Advisor. This strategic move aims to bolster the firm's presence in Miami, strengthening relationships with clients and expanding the wealth management team. An...

Continue Reading
Investors Urged to Act by October: Hims & Hers Health Update

Updated Category News Views 270

Attention Hims & Hers Health Investors Investors holding shares in Hims & Hers Health, Inc. are urged to stay vigilant regarding significant developments affecting their investments. The Company, often simply referred to as Hims, is currently facing securities class action lawsuits filed by investors who believe they suffered financial losses during a specified period....

Continue Reading